Navigation Links
ViroPharma Incorporated Reports First Quarter 2009 Financial Results
Date:4/29/2009

ased bonds. A reconciliation between GAAP and adjusted net income is provided in the Consolidated Statement of Operations - Reconciliation of GAAP Net Income to Adjusted Net Income table included with this release.

The Company believes it is important to share these non-GAAP financial measures with shareholders as they better represent the ongoing economics of the business and reflect how we manage the business. Accordingly, we believe investors' understanding of the Company's financial performance is enhanced as a result of our disclosing these non-GAAP financial measures. Non-GAAP adjusted net income should not be viewed in isolation, or as a substitute for or superior to reported or GAAP net (loss) income. Our definition of non-GAAP financial measures may differ from others.

"The first quarter of 2009 was the first full quarter of our launch of Cinryze; among other highlights, 2,151 doses were shipped to patients in its first full quarter of availability," stated Vincent Milano, ViroPharma's president and chief executive officer. "During the quarter, we also made great strides in expanding patient access to the drug through CINRYZESolutions(TM) and improving the level of HAE awareness among treating physicians. We remain well positioned financially, with $245 million in cash and cash equivalents on our balance sheet."

Continued Milano, "Throughout the remainder of 2009 we will build our momentum in the market for both Cinryze and Vancocin; move our NTCD program for recurrent CDI into clinical studies; and await our June 3, 2009 PDUFA date for the acute indication for Cinryze."

GAAP net loss in the first quarter ended March 31, 2009 was $59.2 million compared to net income of $16.4 million for the same period in 2008. GAAP net loss per share for the quarter ended March 31, 2009 was $0.77 per share, basic and diluted, compared to a GAAP net income per share of $0.23, basic, a
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
2. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. ViroPharma to Present at Three November Healthcare Conferences
5. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
6. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
7. ViroPharma to Present at Three October Healthcare Conferences
8. ViroPharma to Present at Three September Healthcare Conferences
9. ViroPharma To Acquire Lev Pharmaceuticals
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
(Date:5/21/2013)... Minneapolis, MN (PRWEB) May 21, 2013 ... a patented automatic colony counter, announced today that they ... four products , the IncuCount, IntelliCount, InCount and ... price and sophistication are especially useful in food microbiology ... been given an updated look. A bright white ...
(Date:5/21/2013)... May 21, 2013 Possible mold re-infestation in ... according to a report from eagletribune.com posted May 14, 2013, ... case the result is positive, My Cleaning Products offered a ... chemical ingredients. , It was said in the Eagle Tribune ... in the campus sparked after a first-grade classroom was closed ...
(Date:5/21/2013)... Clinovo's new “CDISC Standards: Theory and ... on June 11th, 2013. The TechTrainings are technical hands-on ... next step in their professional career. The class will ... streamed online. , Taught by Sy Truong, President at ... Standards: Theory and Application” class will give an overview ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3Clinovo Launches TechTrainings on CDISC Standards 2
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... GeneLink Biosciences, Inc. (OTCBB: GNLK), a leading consumer ... the stock of its wholly owned direct-selling subsidiary ... (OTCBB: WELL), another public company operating in the ... and Capsalus executed definitive agreements for the sale ...
... 2012 Senior analysts from The Advisory Board Company,s ... Vegas preparing to provide an immediate analysis of the ... Management Systems Society,s HIMSS12 Annual Conference and Exhibition, which ... http://photos.prnewswire.com/prnh/20110802/PH45999LOGO ) By Monday, the ...
Cached Biology Technology:GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy 2Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy 3
(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/18/2013)... (May 18, 2013) An increasing number of ... interventions to resolve, according to research presented at ... study targeting obesity, researchers at the Cleveland Clinic ... unique pattern of exhaled breath compared to their ... organic compound levels that can be correlated to ...
(Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... different gene mutations, but just how these mutations contribute to ... new clue comes from scientists at the University of North ... Their research indicates that early life sun exposure, from birth ... melanomas with BRAF gene mutations. A different mutation, on the ...
... were estimated to be living with Alzheimer’s disease in 2006, ... Hopkins Bloomberg School of Public Health. The researchers also concluded ... than 106 million by 2050. By that time, 43 percent ... to that of a nursing home. The findings were presented ...
... at x-rays of hands, searching out the telltale signs of ... arthritis. With these clinical features at his side, he turns ... genome – to figure out what makes these people susceptible ... finally closed the circle between key genes identified in his ...
Cached Biology News:Sun exposure early in life linked to specific skin cancer gene mutation 2Alzheimer's disease to quadruple worldwide by 2050 2Breakthrough developments in rheumatoid arthritis reported 2Breakthrough developments in rheumatoid arthritis reported 3Breakthrough developments in rheumatoid arthritis reported 4
Form: Ready to use Applications: ELISA...
Request Info...
Form: Concentrated Applications: ELISA...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
Biology Products: